These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35689976)

  • 1. Cortico-cognition coupling in treatment resistant schizophrenia.
    Syeda WT; Wannan CMJ; Merritt AH; Raghava JM; Jayaram M; Velakoulis D; Kristensen TD; Soldatos RF; Tonissen S; Thomas N; Ambrosen KS; Sørensen ME; Fagerlund B; Rostrup E; Glenthøj BY; Skafidas E; Bousman CA; Johnston LA; Everall I; Ebdrup BH; Pantelis C
    Neuroimage Clin; 2022; 35():103064. PubMed ID: 35689976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Cortical Structures and Cognition in Antipsychotic-Naïve Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis.
    Jessen K; Mandl RCW; Fagerlund B; Bojesen KB; Raghava JM; Obaid HG; Jensen MB; Johansen LB; Nielsen MØ; Pantelis C; Rostrup E; Glenthøj BY; Ebdrup BH
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2019 May; 4(5):444-453. PubMed ID: 30420252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered Neuroanatomical Signatures of Patients With Treatment-Resistant Schizophrenia Compared to Patients With Early-Stage Schizophrenia and Healthy Controls.
    Liu C; Kim WS; Shen J; Tsogt U; Kang NI; Lee KH; Chung YC
    Front Psychiatry; 2022; 13():802025. PubMed ID: 35664476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients.
    Matrone M; Kotzalidis GD; Romano A; Bozzao A; Cuomo I; Valente F; Gabaglio C; Lombardozzi G; Trovini G; Amici E; Perrini F; De Persis S; Iasevoli F; De Filippis S; de Bartolomeis A
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110493. PubMed ID: 34883221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia.
    Chan SKW; Pang TSW; Tsui HKH; Suen YN; Yan WC; Tsui CF; Poon LT; Chan CWH; Lo A; Cheung KM; Hui CLM; Chang WC; Lee EHM; Chen EYH; Honer WG
    Psychiatry Res; 2024 Jul; 337():115985. PubMed ID: 38820652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between cognition and white matter microstructure in first-episode antipsychotic-naïve patients with schizophrenia and healthy controls: A multivariate pattern analysis.
    Thomas MB; Raghava JM; Pantelis C; Rostrup E; Nielsen MØ; Jensen MH; Glenthøj BY; Mandl RCW; Ebdrup BH; Fagerlund B
    Cortex; 2021 Jun; 139():282-297. PubMed ID: 33933719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving outcome of treatment-resistant schizophrenia: effects of cognitive remediation therapy.
    Martini F; Spangaro M; Bechi M; Agostoni G; Buonocore M; Sapienza J; Nocera D; Ave C; Cocchi F; Cavallaro R; Bosia M
    Eur Arch Psychiatry Clin Neurosci; 2024 Sep; 274(6):1473-1481. PubMed ID: 38114732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shared and distinct gray matter abnormalities in schizophrenia, schizophrenia relatives and bipolar disorder in association with cognitive impairment.
    Knöchel C; Stäblein M; Prvulovic D; Ghinea D; Wenzler S; Pantel J; Alves G; Linden DE; Harrison O; Carvalho A; Reif A; Oertel-Knöchel V
    Schizophr Res; 2016 Mar; 171(1-3):140-8. PubMed ID: 26833265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression.
    Laywer G; Nyman H; Agartz I; Arnborg S; Jönsson EG; Sedvall GC; Hall H
    BMC Psychiatry; 2006 Aug; 6():31. PubMed ID: 16901336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling cognitive impairment in treatment-resistant schizophrenia patients.
    Frydecka D; Beszłej JA; Gościmski P; Kiejna A; Misiak B
    Psychiatry Res; 2016 Jan; 235():133-8. PubMed ID: 26706131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing Between Treatment-Resistant and Non-Treatment-Resistant Schizophrenia Using Regional Homogeneity.
    Gao S; Lu S; Shi X; Ming Y; Xiao C; Sun J; Yao H; Xu X
    Front Psychiatry; 2018; 9():282. PubMed ID: 30127752
    [No Abstract]   [Full Text] [Related]  

  • 14. Associations Between Structural Covariance Network and Antipsychotic Treatment Response in Schizophrenia.
    Tsugawa S; Honda S; Noda Y; Wannan C; Zalesky A; Tarumi R; Iwata Y; Ogyu K; Plitman E; Ueno F; Mimura M; Uchida H; Chakravarty M; Graff-Guerrero A; Nakajima S
    Schizophr Bull; 2024 Mar; 50(2):382-392. PubMed ID: 37978044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differentiation of deficit and non-deficit schizophrenia based on cognitive functions].
    Polgár P
    Ideggyogy Sz; 2011 Mar; 64(3-4):128-32. PubMed ID: 21545010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the stability and reproducibility of brain-behaviour relationships found using Canonical Correlation Analysis and Partial Least Squares within the ABCD Sample.
    Nakua H; Yu JC; Abdi H; Hawco C; Voineskos A; Hill S; Lai MC; Wheeler AL; McIntosh AR; Ameis SH
    bioRxiv; 2023 Mar; ():. PubMed ID: 36945610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
    de Bartolomeis A; Prinzivalli E; Callovini G; D'Ambrosio L; Altavilla B; Avagliano C; Iasevoli F
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():356-366. PubMed ID: 28887181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mentalizing in schizophrenia: A multivariate functional MRI study.
    Martin AK; Dzafic I; Robinson GA; Reutens D; Mowry B
    Neuropsychologia; 2016 Dec; 93(Pt A):158-166. PubMed ID: 27793657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia.
    Miyazawa A; Kanahara N; Kogure M; Otsuka I; Okazaki S; Watanabe Y; Yamasaki F; Nakata Y; Oda Y; Hishimoto A; Iyo M
    Mol Biol Rep; 2022 Mar; 49(3):2015-2024. PubMed ID: 34845648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.
    Kanchanatawan B; Maes M
    CNS Neurol Disord Drug Targets; 2018; 17(6):473-486. PubMed ID: 29968545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.